| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.41B | 1.15B | 895.40M | 636.40M | 535.82M |
| Gross Profit | 622.11M | 327.89M | 271.65M | 168.20M | 134.35M |
| EBITDA | 227.88M | 165.59M | 124.02M | 60.29M | 58.53M |
| Net Income | 170.03M | 118.83M | 85.98M | 39.40M | 38.32M |
Balance Sheet | |||||
| Total Assets | 4.79B | 3.73B | 2.95B | 2.36B | 2.12B |
| Cash, Cash Equivalents and Short-Term Investments | 2.02B | 1.18B | 1.35B | 774.17M | 664.74M |
| Total Debt | 100.41M | 119.54M | 128.69M | 128.61M | 128.53M |
| Total Liabilities | 3.78B | 2.94B | 2.29B | 1.94B | 1.69B |
| Stockholders Equity | 1.01B | 794.00M | 661.03M | 421.66M | 426.08M |
Cash Flow | |||||
| Free Cash Flow | 402.62M | 300.89M | 335.03M | 206.61M | 173.13M |
| Operating Cash Flow | 408.08M | 305.12M | 338.19M | 208.94M | 175.28M |
| Investing Cash Flow | -366.90M | -243.69M | -493.81M | -193.38M | -183.01M |
| Financing Cash Flow | 411.00K | -4.23M | 130.95M | 2.18M | 1.38M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $2.23B | 7.31 | 40.02% | 0.82% | 8.71% | 17.26% | |
77 Outperform | $2.19B | 12.16 | 18.85% | ― | 22.51% | 2.19% | |
76 Outperform | $1.10B | 11.55 | 9.97% | 4.59% | 13.35% | 16.56% | |
73 Outperform | $2.42B | 5.43 | 52.29% | ― | ― | ― | |
69 Neutral | $2.10B | 17.66 | 7.08% | 2.88% | 16.22% | 69.80% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
58 Neutral | $746.32M | 52.81 | 11.32% | ― | 38.50% | ― |
On December 30, 2025, Skyward Specialty entered into a new unsecured senior delayed draw term loan facility totaling $300 million, split between Tranche A maturing January 1, 2028 and Tranche B maturing July 2, 2029, with pricing tied to term SOFR or a base rate plus a margin, and customary covenants on leverage, capital, ratings and liquidity, as well as a related guaranty from most non-insurance subsidiaries and an amendment to its existing credit agreement to permit pre-funding of revolving loans. Using proceeds from this new facility and its existing credit agreement, the company completed the previously announced acquisition of U.K.-based Apollo Group Holdings Limited on the January 2, 2026 closing date, paying roughly $555 million through $371 million in cash and the issuance of 3.68 million common shares, a move that expands Skyward Specialty’s presence at Lloyd’s of London and broadens its product and geographic reach in specialty insurance markets.
The most recent analyst rating on (SKWD) stock is a Buy with a $69.00 price target. To see the full list of analyst forecasts on Skyward Specialty Insurance Group, Inc. stock, see the SKWD Stock Forecast page.
On December 3, 2025, Skyward Specialty Insurance Group, Inc. announced it has received regulatory and minority shareholder approvals for its acquisition of Apollo Group Holdings Limited, with the transaction expected to close in early 2026. The company also provided its 2026 financial guidance, projecting significant growth in gross written premiums, net income, and adjusted operating income, reflecting the anticipated impact of the Apollo acquisition and its commitment to delivering top quartile results.
The most recent analyst rating on (SKWD) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Skyward Specialty Insurance Group, Inc. stock, see the SKWD Stock Forecast page.